Ramon Ungab, MD
Internal Medicine · Bartlett, TNNPI 1053314104
Payments from drug & device makers
Across 382 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$690
- Amarin Pharma, Inc.$656
- GSK$650
- Pfizer$402
- Johnson & Johnson$347
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,098100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $1,033 |
| Novo Nordisk | 44 | $690 |
| Amarin Pharma, Inc. | 37 | $656 |
| GSK | 57 | $650 |
| Pfizer | 29 | $402 |
| Johnson & Johnson | 25 | $347 |
| Boehringer Ingelheim | 18 | $293 |
| Merck | 19 | $280 |
| AbbVie(2 entities) | 11 | $210 |
| Lilly USA, LLC | 13 | $172 |
| Amgen | 11 | $166 |
| Mylan Specialty L.p. | 12 | $164 |
| Melinta Therapeutics, LLC | 3 | $161 |
| E.r. Squibb & Sons, L.L.C. | 9 | $146 |
| Esperion Therapeutics, Inc. | 8 | $132 |
| Abbott | 6 | $118 |
| Nestle Healthcare Nutrition Inc. | 5 | $91 |
| Sunovion Pharmaceuticals Inc. | 7 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Novartis | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Edwards Lifesciences | 1 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Bayer | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,103 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $93,421 |
| JardianceEmpagliflozin | 69 | $78,109 |
| OzempicSemaglutide | 43 | $57,058 |
| MounjaroTirzepatide | 47 | $55,478 |
| JanuviaSitagliptin Phosphate | 45 | $42,562 |
| FarxigaDapagliflozin Propanediol | 47 | $39,280 |
| XareltoRivaroxaban | 22 | $33,464 |
| TrulicityDulaglutide | 13 | $28,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $24,589 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,912 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $19,635 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $19,177 |
| EntrestoSacubitril/Valsartan | 14 | $19,104 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $14,952 |
| MyrbetriqMirabegron | 18 | $14,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $402 | $93,421100 claims |
| Boehringer IngelheimJardiance, Jentadueto | $293 | $87,17481 claims |
| Lilly USA, LLCMounjaro, Trulicity | $172 | $84,10060 claims |
| MerckJanuvia, Janumet | $280 | $61,73965 claims |
| Novo NordiskOzempic | $690 | $57,05843 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $650 | $41,65852 claims |
| AstraZenecaFarxiga | $1,033 | $39,28047 claims |
| Johnson & JohnsonXarelto | $347 | $33,46422 claims |
| NovartisEntresto | $51 | $19,10414 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $14,06718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bartlett
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.